Results 221 to 230 of about 30,994 (308)

The Postprandial Chronobiome in Interorgan Glucose Homeostasis

Comprehensive Physiology, Volume 16, Issue 4, August 2026.
The postprandial chronobiome framework proposes that meal‐timed oscillations in microbial communities and metabolites may interact with host tissue clocks to shape glucose handling. The liver is the best‐supported temporal interpreter, while phase‐aware human studies are needed to establish causal interorgan effects.
Josko Bozic, Roko Santic, Marko Kumric
wiley   +1 more source

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. [PDF]

Sci Rep
Dan K, Sanada J, Kimura T, Iwamoto Y, Sugisaki T, Iwamoto H, Fushimi Y, Nogami Y, Shirakiya Y, Shimoda M, Nakanishi S, Kaku K, Kaneto H.   +12 more
europepmc   +1 more source

Beyond Weight Loss: Tirzepatide as a Metabolic Disease‐Modifying Strategy for Metabolic Dysfunction‐Associated Steatohepatitis: A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver‐related morbidity and mortality. Its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation,
Zubaier Ahmed, Nashrah Mustafa, Tamanna Sarkar, Hasina Yasmin   +3 more
wiley   +1 more source

Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome. [PDF]

JCEM Case Rep
Liao XC, Huang T, Hong DS, Luo L.
europepmc   +1 more source

Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Highly effective anti‐obesity medications (AOMs) induce substantial weight loss and have renewed debate on appropriate treatment targets. Weight loss comprises reductions in fat mass (FM) and fat‐free mass (FFM), with skeletal muscle (SM) as the major component of FFM.
Anja Bosy‐Westphal, Janna Enderle, Kristina Norman, Manfred J. Müller   +3 more
wiley   +1 more source

GIP is back

Cahiers de Nutrition et de Diététique
Bernard Portha, Junjun Liu
openaire   +1 more source

Calcium Beta‐Hydroxy‐Beta‐Methylbutyrate‐Enriched Nutritional Supplementation During Dietary Weight Loss in Adults With Obesity: A Randomized Controlled Trial

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Dietary and pharmacologic weight loss can reduce skeletal muscle. Whether calcium beta‐hydroxy‐beta‐methylbutyrate (CaHMB)‐enriched supplementation preserves muscle while promoting fat loss in adults with obesity remains uncertain. We evaluated a CaHMB‐enriched nutritional supplement during energy restriction.
Jiaojiao Jiang, Yuxiang Liang, Renjie Wang, Wenhua Jiang, Xiaofan Jing, Ming Yang   +5 more
wiley   +1 more source

The risk of digestive tract complications in patients with gastrointestinal lymphoma: a propensity score study. [PDF]

BMC Gastroenterol
Zhao Y, Zhang X, Zhou Y, Dai N, Li Y, He S.   +5 more
europepmc   +1 more source

Imeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Sarcopenia is a major contributor to frailty and mortality in ageing and obesity and is tightly linked to metabolic dysfunction. Imeglimin is a first‐in‐class oral hypoglycaemic agent targeting mitochondrial function; however, despite the central role of mitochondria in skeletal muscle homeostasis, its effects on skeletal muscle ...
Yangli Ye, Diandian Qian, Ikumi Nomura, Naoki Kobayashi, Yukiko Shimizu, Tadashi Okamura, Motoharu Awazawa, Kohjiro Ueki   +7 more
wiley   +1 more source

Gips

, 2004
openaire   +1 more source